Our Partners
Aetheris Labs
Aetheris Labs is a premier technology partner specializing in secure, AI-driven solutions for the life sciences sector. The company excels as a data protection expert, guiding clients through complex data governance and strategic IT decisions. Its core strength lies in transforming unstructured data into structured, compliant insights through a best-in-class Data Management Platform.
Aetheris Labs leverages predictive analytics to deliver AI-Powered Solutions that automate operations, enhance decision-making, and anticipate future needs. With an agile and customer-centric approach, the company empowers businesses by bridging the gap between cutting-edge technology and practical application, ensuring scalable growth and robust security in a digital world.
Shineco Inc. (NASDAQ: SISI)
Shineco Inc. (NASDAQ: SISI) is a pioneering biotechnology company transitioning into a global cell economy infrastructure provider. Leveraging its expertise in induced pluripotent stem cell (iPSC) technology, the company is building a decentralized, blockchain-based ecosystem for biological cell assets.
Through strategic acquisitions and partnerships, Shineco is establishing a verifiable framework for the digital management, circulation, and real-world redemption of on-chain cell assets.
This integrates its offline "storage + reinfusion" health network with digital ERC-1400/ERC-20 standard vouchers, enabling cross-enterprise service redemption. By focusing on standardization, compliance, and scenario exploration, Shineco is advancing the RWA ecosystem from technical integration to widespread, practical application.
Wealth Index Capital Group
Wealth Index Capital Group is a leading, full-service financial institution headquartered in China, providing comprehensive wealth management and investment solutions to a discerning clientele.
The firm specializes in global asset allocation, offering tailored services in private equity, venture capital, fixed income, and family office advisory. Leveraging deep market intelligence and a robust research platform, its team of seasoned experts constructs diversified portfolios designed to preserve and grow wealth across generations.
Committed to integrity and client-centric values, Wealth Index Capital Group delivers sophisticated strategies and exclusive access to premium investment opportunities, aiming to be a trusted partner in achieving its clients' long-term financial objectives and securing their legacies.
Future FinTech Group (FTFT)
FTTFT International Securities is dedicated to building a globally leading financial services platform, providing clients with comprehensive one-stop financial services and solutions. Established in 2010 and affiliated with the FTTFT Financial Technology Group (NASDAQ: FTFT), the company is a licensed corporation approved by the Hong Kong Securities and Futures Commission (SFC Central No.: ATR516), holding licenses for Type 1, Type 2, and Type 4 regulated activities.
With over 20 years of experience, FTTFT International Securities has successfully guided more than 60 companies to list overseas across 26 countries. The team comprises seasoned professionals from top-tier firms like UBS, Mitsubishi, Geely, and SPDB, with deep expertise in finance, investment banking, and corporate governance.
Global Presence
Headquartered in Hong Kong, FTTFT operates branches in New York, London, Dubai, Shenzhen, Beijing, and Xi'an, ensuring seamless support for clients worldwide.
Beijing Tianyi Yuanfang Biotechnology
Beijing Tianyi Yuanfang Biotechnology Co., Ltd. (referred to as "Tianyi Yuanfang Biotech") was established in 2020. Driven by cell biotechnology, the company focuses on the development and industrial application of bioactive ingredients such as cell active extracts. It is dedicated to building a cell-integrated industrial ecosystem, continually pursuing its mission of "Cell Technology Serving Human Health and Beauty." Highlights:
-
20 years of industry experience, resulting in 11 invention patents, 1 PCT patent, 4 pending patents, and 20+ SCI papers.
-
60+ proprietary technologies (trade secrets)
-
10+ domestic and international invention patents
-
10+ trademark registrations
Biotech & Biomedicine (Shenyang) Group
Developer of life science innovations designed for advancing new technologies, drugs, and products in the biomedical field in particular diagnostics both clinical and molecular. The company focuses on building an integrated academic, research, production, and application ecosystem, providing a comprehensive value chain for life sciences R&D and industrialization.